Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer.
Laia PiquéAlexia Martinez de PazDavid PiñeyroAnna Martinez-CardusManuel Castro de MouraPere Llinàs-AriasFernando SetienJorge Gómez-MiragayaEva Gonzalez-SuarezStefan SigurdssonJon G JonassonAlberto VillanuevaAugust VidalVeronica DavalosManel EstellerPublished in: Oncogene (2019)
Human tumors show altered patterns of protein isoforms that can be related to the dysregulation of messenger RNA alternative splicing also observed in transformed cells. Although somatic mutations in core spliceosome components and their associated factors have been described in some cases, almost nothing is known about the contribution of distorted epigenetic patterns to aberrant splicing. Herein, we show that the splicing RNA-binding protein CELF2 is targeted by promoter hypermethylation-associated transcriptional silencing in human cancer. Focusing on the context of breast cancer, we also demonstrate that CELF2 restoration has growth-inhibitory effects and that its epigenetic loss induces an aberrant downstream pattern of alternative splicing, affecting key genes in breast cancer biology such as the autophagy factor ULK1 and the apoptotic protein CARD10. Furthermore, the presence of CELF2 hypermethylation in the clinical setting is associated with shorter overall survival of the breast cancer patients carrying this epigenetic lesion.
Keyphrases
- binding protein
- dna methylation
- endothelial cells
- gene expression
- induced pluripotent stem cells
- cell death
- pluripotent stem cells
- transcription factor
- induced apoptosis
- endoplasmic reticulum stress
- oxidative stress
- papillary thyroid
- signaling pathway
- cell proliferation
- cancer therapy
- drug delivery
- nucleic acid
- amino acid
- heat shock
- lymph node metastasis
- free survival